There is no specific vaccine-Cosentyx (secukinumab) interaction timeline to follow, as the manufacturer, Novartis, does not provide clear guidance on this matter [1]. However, it is generally recommended that live vaccines be administered at least 4 weeks prior to starting Cosentyx, and ideally, live vaccines should be given 12 weeks before initiating Cosentyx [1][2]. This recommendation is based on the potential risk of immunosuppression associated with Cosentyx, which could lead to reduced vaccine effectiveness or an increased risk of adverse reactions [2].

It is important to note that the decision to administer vaccines while on Cosentyx should be made on a case-by-case basis, taking into account the patient's individual risk factors and the specific vaccine being considered [2]. Healthcare providers should consult the Centers for Disease Control and Prevention (CDC) guidelines for vaccination of immunocompromised patients, as well as the vaccine-specific prescribing information [2].

In summary, while there is no specific vaccine-Cosentyx interaction timeline, it is generally advised to administer live vaccines at least 4 weeks prior to starting Cosentyx and ideally, 12 weeks before [1][2]. The decision to administer vaccines while on Cosentyx should be made on a case-by-case basis, considering the patient's individual risk factors and the specific vaccine [2].

Sources:
[1] DrugPatentWatch.com. Cosentyx (secukinumab) Drug Profile. <https://www.drugpatentwatch.com/drugs/cosentyx>.
[2] Novartis Pharmaceuticals Corporation. Cosentyx (secukinumab) injection, for subcutaneous use. Full Prescribing Information. January 2022. <https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/cosentyx.pdf>.